Search

Alkermes PLC

Suletud

SektorTervishoid

45.66 1.69

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

44.4

Max

45.48

Põhinäitajad

By Trading Economics

Sissetulek

67M

501K

Müük

103M

496M

P/E

Sektori keskmine

116.947

50.373

Aktsiakasum

0.52

Kasumimarginaal

0.101

Töötajad

2,050

EBITDA

76M

54M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+29.81% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

3. nov 2026

Turustatistika

By TradingEconomics

Turukapital

-1.3B

7.5B

Eelmine avamishind

43.97

Eelmine sulgemishind

45.66

Alkermes PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. nov 2026, 21:04 UTC

Event

Alkermes initiates a phase 2 study for ALKS 7290 as an adjunctive therapy for major depressive disorder, amid broader market declines.

29. okt 2026, 20:06 UTC

Alkermes Plc shares are advancing, showing a modest gain since Wednesday's close and remaining notably above their 20-day moving average.

28. okt 2026, 20:52 UTC

Alkermes Plc shares are trading modestly lower in after-market hours, reflecting the broader market's significant decline amid recent economic data and the Fed's cautious outlook.

27. okt 2026, 19:46 UTC

Alkermes Plc shares fell modestly after retracing from an early high, though they remain above the 20-day moving average and near the upper end of their one-month range.

26. okt 2026, 19:46 UTC

Alkermes Plc is trading higher, showing strength above its 20-day moving average and near the upper end of its one-month range.

23. okt 2026, 20:07 UTC

Alkermes Plc shares fell amid a broader market decline, influenced by mixed economic indicators and rising oil prices raising inflation concerns.

22. okt 2026, 20:07 UTC

Alkermes Plc shares advanced, trading higher after Wednesday's close, despite pulling back from a session high earlier in the day.

21. okt 2026, 20:01 UTC

Alkermes Plc shares fell sharply after reaching an early high, declining to their lowest point before 3:30 PM.

20. okt 2026, 20:08 UTC

Alkermes Plc is trading higher, maintaining gains since Monday, despite pulling back from earlier session highs, and remains above its 20-day moving average.

19. okt 2026, 20:01 UTC

News

Piper Sandler reiterates Overweight rating on Alkermes and sets price target at $65 following management meetings.

17. okt 2026, 00:02 UTC

Alkermes Plc's shares advanced modestly in after-market trading on Friday, following three consecutive higher daily closes and a notable rise during the session.

16. okt 2026, 23:31 UTC

Alkermes Plc has advanced in after-market trading, reaching its highest level since Friday's close, continuing a stronger trend from recent sessions.

15. okt 2026, 20:01 UTC

Alkermes Plc shares are advancing, having gained since Wednesday's close, peaking nearly 4% earlier before pulling back slightly.

14. okt 2026, 20:07 UTC

Event

Alkermes plans to present two oral presentations and six posters at the European Sleep Research Society’s Congress in October 2026.

12. okt 2026, 19:16 UTC

Alkermes Plc shares fell, continuing a trend of weakness, and are positioned below their 20-day moving average near the lower end of their one-month range.

9. okt 2026, 21:51 UTC

Alkermes Plc is declining in after-market trading, reaching its lowest point since Friday's close and remaining significantly below its 20-day moving average.

8. okt 2026, 20:01 UTC

Alkermes Plc shares fell, reversing a trend of higher daily closes amid a broader shift in market performance.

7. okt 2026, 19:25 UTC

Alkermes Plc shares fell modestly, retracing from a late morning high, contributing to a lower performance since Tuesday's close and remaining below the 20-day moving average.

6. okt 2026, 19:51 UTC

Alkermes Plc shares fell sharply, continuing a notable decline since Monday's close amid broader market conditions and trading below its 20-day moving average.

5. okt 2026, 23:40 UTC

Alkermes Plc is trading higher in after-market hours, extending its upward trend after three consecutive sessions of gains amid positive biotechnology sector performance.

2. okt 2026, 19:26 UTC

Alkermes Plc is trading sharply higher, recovering from earlier lows, despite remaining below its 20-day moving average and near the lower end of its one-month range.

1. okt 2026, 22:50 UTC

Alkermes Plc declined in after-market trading, moving lower since Thursday's close and positioning the stock below its 20-day moving average.

29. sept 2026, 20:07 UTC

Alkermes Plc closed higher in Tuesday's trading session, despite notable volatility, finishing above Monday's close but below its 20-day moving average.

28. sept 2026, 19:16 UTC

News

Alkermes Plc shares fell modestly, continuing a decline since Friday and trading near the lower end of their one-month range.

24. sept 2026, 20:01 UTC

News

Alkermes Plc shares fell sharply as Goldman Sachs resumed coverage with a Neutral rating and a $50.00 price target, contributing to the stock's decline.

23. sept 2026, 20:07 UTC

Alkermes Plc shares fell sharply today, hitting a midday low and remaining below the 20-day moving average after earlier strength in the session.

22. sept 2026, 20:01 UTC

Event

Alkermes Plc reported positive results from a phase 1 study for ALKS 7290, yet shares fell sharply, remaining below their 20-day moving average.

21. sept 2026, 23:51 UTC

Event

Alkermes Plc's stock is declining in after-market trading despite positive phase 1 results for ALKS 7290, remaining below its 20-day moving average.

18. sept 2026, 20:02 UTC

Alkermes Plc shares fell sharply, reversing recent upward momentum, with a decline following a series of higher daily closes since Thursday's close.

17. sept 2026, 19:36 UTC

Alkermes Plc is trading higher, having previously peaked, but remains below its 20-day moving average and near the lower end of its one-month range.

Võrdlus sarnastega

Hinnamuutus

Alkermes PLC Prognoos

Hinnasiht

By TipRanks

29.81% tõus

12 kuu keskmine prognoos

Keskmine 58.273 USD  29.81%

Kõrge 83 USD

Madal 38 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Alkermes PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

12 ratings

8

Osta

3

Hoia

1

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat